Back Back
Immunotherapy in NSCLC

CE / CME

Multidisciplinary Perspectives: Updates in Immunotherapy for Treating NSCLC

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: March 18, 2024

Expiration: March 17, 2025

Zofia Piotrowska
Zofia Piotrowska, MD
CME/CE Information

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
Continue to Activity
1.

Patient Case: Newly Diagnosed Advanced NSCLC With PD-L1 ≥50%



  • 60-yr-old woman with a smoking history noted a mass at the base left-hand side of her neck, and her physician found a 2-cm nonmobile lymph node

  • CT scan showed bilateral lung masses (largest 2 cm), mediastinal adenopathy, and bilateral supraclavicular adenopathy

  • PET confirmed CT results, with evidence of liver involvement

  • Liver biopsy was positive for adenocarcinoma

  • PD-L1 70%, NGS positive for KRAS G12V

  • She is asymptomatic with no brain metastases on MRI

  • She is otherwise healthy except for osteoarthritis and an eGFR of 40 mL/min

In your current practice, which of the following regimens would you recommend for this patient?

2.

Patient Case: Newly Diagnosed Adv NSCLC With PD-L1 1%-49%



  • 60-yr-old woman with a smoking history noted a mass at the base left-hand side of her neck, and her physician found a 6-cm nonmobile lymph node

  • CT scan showed bilateral lung masses (largest 5 cm), mediastinal adenopathy, and bilateral supraclavicular adenopathy

  • PET confirmed CT results, with evidence of liver involvement

  • Liver biopsy was positive for adenocarcinoma

  • PD-L1 40%, NGS positive for KRAS G12V

  • She is symptomatic and in need of supplemental oxygen, with no brain metastases on MRI

  • She is otherwise healthy except for osteoarthritis and an eGFR of 60 mL/min

In your current practice, which of the following regimens would you recommend for this patient?

3.

Based on available evidence, indications, and expert recommendations, patients with resectable, early-stage NSCLC and which of the following levels of PD-L1 expression would benefit from perioperative (neoadjuvant and adjuvant) pembrolizumab?

4.

How confident are you in developing multidisciplinary team strategies to manage AEs in patients with advanced NSCLC receiving an ICI plus chemotherapy?

Continue to Activity